Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market

Viking Therapeutics CEO Brian Lian said pharmaceutical companies are showing broader and deeper strategic interest in weight-loss drug deals than is immediately visible, as the global obesity treatment market continues to gain momentum. Speaking at the J.P. Morgan Healthcare Conference on Monday, Lian highlighted that more drugmakers are closely monitoring the space, driven by the massive commercial potential of next-generation weight-loss therapies.

The weight-loss drug market is rapidly expanding, with analysts estimating it could surpass $150 billion in annual sales by the end of the decade. This growth is being fueled by multiple factors, including expanded clinical uses beyond obesity, increased patient awareness and adoption, improvements in manufacturing capacity, and a strong pipeline of innovative therapies designed to improve efficacy and safety.

According to Lian, pharmaceutical companies are actively evaluating different strategies to enter or expand their presence in the obesity treatment market. One approach involves acquiring or licensing early-stage drug candidates, which may come at a lower cost but carry higher development risk. Alternatively, companies may choose to invest in proven weight-loss drugs that have already demonstrated clinical success, though these assets typically command significantly higher valuations.

“I think the interest is probably broader than is visible,” Lian said, noting that many potential partners are “circling around the space and very intrigued” by the long-term opportunities in metabolic and weight-loss treatments.

Recent high-profile deals underscore the intensity of competition in the sector. In November, Pfizer acquired Metsera for $10 billion after a competitive bidding process that included Novo Nordisk, further highlighting the urgency among major pharmaceutical companies to secure a foothold in the fast-growing market.

Lian previously stated during Viking Therapeutics’ third-quarter earnings call in October that the company is open to external partnerships or acquisition interest, which he indicated would be his preferred outcome. However, he also emphasized that Viking is fully prepared to continue developing its weight-loss drug portfolio independently if a strategic deal does not materialize.

As pharmaceutical giants race to capitalize on the booming obesity drug market, Viking Therapeutics remains well-positioned amid increasing investor and industry attention.